Investor Longitude Capital Partners II, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Longitude Capital Partners II, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-10-18 13D/A KALA / KALA BIO, Inc. 108,239 108,239
2023-08-18 13D/A RXST / RxSight, Inc. 2,539,037 1,774,559
2023-06-05 13D/A RXST / RxSight, Inc. 2,506,972 2,539,037
2023-03-16 13D/A APTX / Aptinyx Inc. 3,644,551 192,805
2023-02-14 13D/A KALA / KALA BIO, Inc. 5,457,030 108,239
2023-02-14 13D/A APTX / Aptinyx Inc. 3,506,744 3,644,551
2023-02-14 13G/A RPID / Rapid Micro Biosystems, Inc. 4,192,547 4,189,845
2023-01-03 13D/A VERO / Venus Concept Inc. 3,691,349 3,466,118
2022-02-15 13G RPID / Rapid Micro Biosystems, Inc. 4,192,547 4,192,547
2021-08-13 13D RXST / RxSight, Inc. 2,506,972
2021-02-12 13G PCVX / Vaxcyte, Inc. 3,108,780
2020-03-23 13D/A KALA / KALA BIO, Inc. 2,895,366 5,457,030
2020-02-12 13G/A 0HBB / Aimmune Therapeutics Inc 6,191,528 6,215,278
2020-02-12 13G/A NBRV / Nabriva Therapeutics Plc 4,012,375 4,256,527
2020-02-12 13D/A APTX / Aptinyx Inc. 3,190,079 3,506,744
2019-11-18 13D VERO / Venus Concept Inc. 3,691,349
2019-02-12 13G/A 0HBB / Aimmune Therapeutics Inc 6,158,435 6,191,528
2018-10-12 13D KALA / KALA BIO, Inc. 2,278,506 2,895,366
2018-08-07 13G NBRV / Nabriva Therapeutics Plc 4,012,375
2018-07-06 13D TCDA / Tricida Inc 3,021,924
2018-07-02 13D APTX / Aptinyx Inc. 3,190,079
2018-02-12 13G KALA / KALA BIO, Inc. 2,278,506
2018-02-12 13G/A 0HBB / Aimmune Therapeutics Inc 6,138,680 6,158,435
2017-02-21 13G/A 0HBB / Aimmune Therapeutics Inc 6,138,680 6,138,680
2017-02-10 13G/A 0HBB / Aimmune Therapeutics Inc 7,552,900 6,138,680
2016-01-29 13G 0HBB / Aimmune Therapeutics Inc 7,552,900